Abstract Details

Title The Parkinson Progression Marker Initiative (PPMI) - Baseline Data

Topic Movement Disorders

Presentation(s) S03 - (-)

Poster/Presentation
Number 007

Objective

Background Lack of progression biomarkers has been a major roadblock to studies investigating potential disease modifying PD drugs.

Design/Methods Recently diagnosed PD (n=400) and healthy volunteers (HV) (n=200) are followed longitudinally for clinical, imaging and biospecimen biomarkers using standardized data acquisition protocols at 24 clinical sites. All study data is integrated into the PPMI study database. Access to data and biospecimens is available at www.ppmi-info.org.

Results PPMI is ongoing and as of 01Oct2012 has enrolled 298 PD, mean age 62.1, (66% Male:34% Female) and 155 HV, mean age 59.3 (59% Male:41% Female). The total MDS UPDRS for PD is 33.2 compared to 4.5 for HV. Baseline MoCA, GDS, and SCOPA-AUT are 27.1, 2.2, 9.7 for PD subjects and 28.3, 1.4, 5.9 for HV. CSF was acquired from > 95% of all subjects. Dopamine transporter (DAT) imaging, used as an inclusion criteria, excluded 12-15% from the PD cohort due to scans without dopaminergic deficit. DAT striatal SBR for PD is 3.97 vs. 6.65 for HV. Over 32,300 downloads and 16 biospecimen requests from the PPMI website have already occurred.

Conclusions Recruitment and comprehensive assessment of PD and HV subjects in PPMI is feasible. Acquisition of CSF from all study subjects has been successful. Public access of PPMI data and biospecimen has resulted in wide use of PPMI data. A prodromal-PPMI cohort defined by hyposmia, REM behavior disorder and/or LRRK2 mutation, plus DAT deficit is planned to begin enrollment in Jan2013. A full list of authors is provided at www.ppmi-info.org.

Authors/Disclosures
Kenneth L. Marek, MD (IND) PRESENTER	Dr. Marek has received personal compensation for serving as an employee of IND. Dr. Marek has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for invicro. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biohaven. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for takeda. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Denali. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Koneksa. Dr. Marek has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xingimaging. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuron23. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Marek has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Marek has received research support from Michael J Fox Foundation.
David E. Blum, MD	Dr. Blum has received personal compensation for serving as an employee of Neurona Therapeutics. Dr. Blum has stock in Neurona Therapeutics.

��ɫ��

��ɫ��